• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

德克萨斯药物治疗算法项目:德克萨斯关于重度抑郁症药物治疗共识会议小组报告

The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.

作者信息

Crismon M L, Trivedi M, Pigott T A, Rush A J, Hirschfeld R M, Kahn D A, DeBattista C, Nelson J C, Nierenberg A A, Sackeim H A, Thase M E

机构信息

College of Pharmacy, University of Texas at Austin, 78712, USA.

出版信息

J Clin Psychiatry. 1999 Mar;60(3):142-56.

PMID:10192589
Abstract

BACKGROUND

This article describes the development of consensus medication algorithms for the treatment of patients with major depressive disorder in the Texas public mental health system. To the best of our knowledge, the Texas Medication Algorithm Project (TMAP) is the first attempt to develop and prospectively evaluate consensus-based medication algorithms for the treatment of individuals with severe and persistent mental illnesses. The goals of the algorithm project are to increase the consistency of appropriate treatment of major depressive disorder and to improve clinical outcomes of patients with the disorder.

METHOD

A consensus conference composed of academic clinicians and researchers, practicing clinicians, administrators, consumers, and families was convened to develop evidence-based consensus algorithms for the pharmacotherapy of major depressive disorder in the Texas mental health system. After a series of presentations and panel discussions, the consensus panel met and drafted the algorithms.

RESULTS

The panel consensually agreed on algorithms developed for both nonpsychotic and psychotic depression. The algorithms consist of systematic strategies to define appropriate treatment interventions and tactics to assure optimal implementation of the strategies. Subsequent to the consensus process, the algorithms were further modified and expanded iteratively to facilitate implementation on a local basis.

CONCLUSION

These algorithms serve as the initial foundation for the development and implementation of medication treatment algorithms for patients treated in public mental health systems. Specific issues related to adaptation, implementation, feasibility testing, and evaluation of outcomes with the pharmacotherapeutic algorithms will be described in future articles.

摘要

背景

本文介绍了得克萨斯州公共精神卫生系统中用于治疗重度抑郁症患者的共识药物治疗算法的开发情况。据我们所知,得克萨斯州药物算法项目(TMAP)是首次尝试开发并前瞻性评估基于共识的药物治疗算法,用于治疗严重和持续性精神疾病患者。该算法项目的目标是提高重度抑郁症适当治疗的一致性,并改善该疾病患者的临床结局。

方法

召开了一次由学术临床医生和研究人员、执业临床医生、管理人员、消费者及家属组成的共识会议,以制定得克萨斯州精神卫生系统中重度抑郁症药物治疗的循证共识算法。经过一系列报告和小组讨论后,共识小组开会并起草了这些算法。

结果

该小组就为非精神病性抑郁症和精神病性抑郁症制定的算法达成了共识。这些算法包括定义适当治疗干预措施的系统策略以及确保策略最佳实施的策略。在达成共识过程之后,这些算法经过反复修改和扩展,以促进在当地的实施。

结论

这些算法为公共精神卫生系统中患者药物治疗算法的开发和实施奠定了初步基础。未来的文章将描述与药物治疗算法的适应性、实施、可行性测试及结果评估相关的具体问题。

相似文献

1
The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder.德克萨斯药物治疗算法项目:德克萨斯关于重度抑郁症药物治疗共识会议小组报告
J Clin Psychiatry. 1999 Mar;60(3):142-56.
2
Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder.德克萨斯药物算法项目:双相情感障碍患者治疗算法的开发与可行性测试
J Clin Psychiatry. 2001 Jun;62(6):439-47.
3
Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.德克萨斯药物治疗算法项目中重度抑郁症患者的临床结果。
Arch Gen Psychiatry. 2004 Jul;61(7):669-80. doi: 10.1001/archpsyc.61.7.669.
4
Mental health care from the public perspective: the Texas Medication Algorithm Project.
J Clin Psychiatry. 1999;60 Suppl 3:16-20; discussion 21.
5
The Texas Children's Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-Deficit/Hyperactivity Disorder.德克萨斯儿童用药算法项目:德克萨斯儿童注意缺陷/多动障碍药物治疗共识会议小组报告。第一部分。注意缺陷/多动障碍。
J Am Acad Child Adolesc Psychiatry. 2000 Jul;39(7):908-19. doi: 10.1097/00004583-200007000-00021.
6
Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.2000年德克萨斯双相情感障碍药物治疗共识会议小组报告。
J Clin Psychiatry. 2002 Apr;63(4):288-99. doi: 10.4088/jcp.v63n0404.
7
Algorithms for optimizing the treatment of depression: making the right decision at the right time.
Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S222-9. doi: 10.1055/s-2003-45134.
8
Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms.德克萨斯药物算法项目:药物算法的定义、原理及开发方法
J Clin Psychiatry. 1998 Jul;59(7):345-51.
9
Algorithms in clinical psychiatry: a stepped approach toward the path to recovery.临床精神病学中的算法:通往康复之路的逐步方法。
Psychopharmacol Bull. 2002 Summer;36 Suppl 2:142-9.
10
The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.
J Am Acad Child Adolesc Psychiatry. 1999 Nov;38(11):1442-54. doi: 10.1097/00004583-199911000-00020.

引用本文的文献

1
Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review.苯二氮䓬类药物及苯二氮䓬受体激动剂在患有抑郁症、焦虑症和失眠症的成人中使用的处方及减药指南:一项国际范围综述
EClinicalMedicine. 2024 Mar 13;70:102507. doi: 10.1016/j.eclinm.2024.102507. eCollection 2024 Apr.
2
Treatment of schizophrenia evaluated via the pharmacopsychometric triangle-An integrative approach with emphasis on well-being and functioning.通过药物心理测量三角评估精神分裂症的治疗——一种强调幸福感和功能的综合方法。
Schizophrenia (Heidelb). 2023 Dec 16;9(1):88. doi: 10.1038/s41537-023-00420-6.
3
Feasibility and acceptability of a novel telepsychiatry-delivered precision prescribing intervention for anxiety and depression.
一种新型的通过远程精神病学提供的针对焦虑和抑郁的精准处方干预措施的可行性和可接受性。
BMC Psychiatry. 2022 Jul 19;22(1):483. doi: 10.1186/s12888-022-04113-9.
4
Within Clinic Reliability and Usability of a Voice-Based Amazon Alexa Administration of the Patient Health Questionnaire 9 (PHQ 9).基于语音的亚马逊 Alexa 版患者健康问卷 9(PHQ 9)在诊所中的可靠性和可用性。
J Med Syst. 2022 May 10;46(6):38. doi: 10.1007/s10916-022-01816-0.
5
Modeling Heterogeneous Brain Dynamics of Depression and Melancholia Using Energy Landscape Analysis.使用能量景观分析对抑郁症和忧郁症的异质性脑动力学进行建模。
Front Psychiatry. 2021 Nov 25;12:780997. doi: 10.3389/fpsyt.2021.780997. eCollection 2021.
6
Adherence to Desvenlafaxine Versus Usual Care and Its Impact on Health Outcomes: A Comparative Real-world Clinical Study.度洛西汀与常规治疗的依从性及其对健康结局的影响:一项比较真实世界的临床研究。
Clin Drug Investig. 2021 Dec;41(12):1055-1066. doi: 10.1007/s40261-021-01086-7. Epub 2021 Nov 6.
7
Study protocol for the antidepressant advisor (ADeSS): a decision support system for antidepressant treatment for depression in UK primary care: a feasibility study.抗抑郁药顾问(ADeSS)研究方案:英国初级保健中用于治疗抑郁症的抗抑郁药治疗的决策支持系统:一项可行性研究。
BMJ Open. 2020 May 24;10(5):e035905. doi: 10.1136/bmjopen-2019-035905.
8
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.抑郁门诊患者暴露于西酞普兰/艾司西酞普兰及其反应的代谢组学特征。
Transl Psychiatry. 2019 Jul 4;9(1):173. doi: 10.1038/s41398-019-0507-5.
9
VitalSign: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression.生命体征:一种用于抑郁症通用筛查和基于测量的护理的初级保健优先(PCP优先)模式。
Pharmaceuticals (Basel). 2019 May 14;12(2):71. doi: 10.3390/ph12020071.
10
Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications.细胞色素P450 2C19慢代谢型在难治性抑郁症中的表现:对治疗和诊断的启示
Front Pharmacol. 2019 Feb 19;10:83. doi: 10.3389/fphar.2019.00083. eCollection 2019.